*****
Summary of Description:
Lew Cantley, Professor of cancer biology and Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College in NYC, discusses his groundbreaking discovery of phosphoinositide 3-kinase (PI3K) and its implications for cancer treatment in a podcast episode of The Peter Attia Drive. He emphasizes the metabolic nature of cancer and the connection between sugar consumption, insulin resistance, and tumor growth. Cantley also talks about various therapies being tested and used, including the possibility of pairing prescriptive nutritional therapies with drugs like PI3K inhibitors for increased efficacy. Additionally, he highlights his new clinical trial enrolling stage 4 breast cancer and endometrial cancer patients.
*****
The Peter Attia Drive has released an intriguing episode featuring Lew Cantley, a Professor of cancer biology and Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College in NYC. Throughout the episode, Cantley walks listeners through his discovery of phosphoinositide 3-kinase (PI3K) and the various implications this has for the care of cancer patients.
The episode is full of new and interesting science-backed notions regarding the metabolic nature of cancer cells. Cantley explains this through his research into the relationship between sugar consumption, insulin resistance, and tumor growth. He provides a more nuanced explanation of the Warburg Effect and the connection between obesity, insulin resistance, and cancer. Moreover, Cantley sheds light on various combinations of therapies that are being tested and used, including the possibility of pairing prescriptive nutritional therapies to increase the efficacy of drugs like PI3K inhibitors.
Towards the end of the episode, Cantley also discusses his exciting new clinical trial that is now enrolling patients with stage 4 breast cancer and endometrial cancer. The prospect of pairing diet with drug could be the future of cancer treatment, making this a fascinating and important episode for anyone interested in the topic.
If you’re looking to learn science through the lens of discovery, this is an excellent episode to listen to. Cantley’s insights and research could have a significant impact on the way we manage and treat cancers, making it all the more important to tune in and learn about the groundbreaking work he’s been doing.
*****
Source Description
Original release date: 5/11/20
In this episode, Lew Cantley, Professor of cancer biology and Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College in NYC, walks us through his amazing discovery of phosphoinositide 3-kinase (PI3K) and the implications for the care of patients with cancer. He explains various combinations of therapies being tested and used, including the possibility of pairing prescriptive nutritional therapies to increase the efficacy of drugs like PI3K inhibitors. Lew also explains the metabolic nature of cancer through the lens of his research into the connection between sugar consumption, insulin resistance, and tumor growth. Additionally, Lew provides some details about his exciting new clinical trial that is just now enrolling patients with stage 4 breast cancer and endometrial cancer.
We discuss:
-Teaching science through the lens of discovery—a better approach to learning science [5:15];
-The metabolic nature of cancer, mitochondria, and a more nuanced explanation of the Warburg Effect [8:30];
-The observation that convinced Lew to stop eating sugar [20:15];
-The connection between obesity, insulin resistance, and cancer [25:30];
-Sugar consumption and tumor growth—What did Lew’s 2019 paper find? [32:00];
-Natural sugar vs. HFCS, fruit vs. fruit juice, insulin response and cancer growth [43:00];
-Increasing efficacy of PI3K inhibitors with ketogenic diets, SGLT2 inhibitors, and metformin [53:30];
-Lew’s clinical trial enrolling stage 4 breast cancer and endometrial cancer patients [1:07:30];
-Pairing diet with drug could be the future of cancer treatment [1:09:30];
-PI3K inhibitors on the market, alpha vs. delta isoform, and the possibility of pairing them with a food prescription [1:16:15];
-What questions will Lew be focused on in the next chapter of his career? [1:22:15];
-Lew’s early work that ultimately led to the discovery of PI3K [1:27:30];
-Studying the mechanism by which mitochondria make ATP [1:30:45];
-How understanding the mechanism by which insulin drove glucose uptake into a cell got Lew closer to finding PI3K [1:38:15];
-How Lew knew PI3K was important in driving growth of cancer cells [1:55:00];
-Lew’s unlikely observation of phosphorylation at the 3′ position of the inositol ring resulting in the formation of phosphatidylinositol-3-phosphate [1:59:00]; and
-More.
Show notes page: https://peterattiamd.com/lewcantley/
——–
About:
The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 30 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.
Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life).
Learn more: https://peterattiamd.com
Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe
Sign up to receive Peter’s email newsletter: https://peterattiamd.com/newsletter
Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG
Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle
[vid_tags]
Comments are closed